.
MergerLinks Header Logo

Announced

Completed

Gemphire Therapeutics and NeuroBo Pharmaceuticals completed their merger.

Financials

Edit Data
Transaction Value-
Consideration TypeOrdinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

pharmaceuticals & biotechnology

biopharmaceuticals

Private

Friendly

United States

Pharmaceuticals

Merger

Completed

Single Bidder

Majority

Synopsis

Edit

Gemphire Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease, and NeuroBo Pharmaceuticals, a privately-held clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases, completed their merger. Financial terms were not disclosed. "We are excited about the opportunities and resources that will become available to NeuroBo and its therapeutic pipeline as a result of the merger. As we move towards developing both NB-01 and NB-02, we believe that having shares publicly traded on Nasdaq will provide greater opportunity to advance our therapeutic pipeline and corporate strategy," John L. Brooks III, NeuroBo Pharmaceuticals President and Chief Executive Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US